Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

What is the Market Forecast for the Drugs in Development for COVID-19

This image opens in the lightbox

News provided by

Visiongain

06 Apr, 2020, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

Novel Coronavirus (COVID-19) Drugs in Development Market Forecast 2020-2030

Revenue Prospects by Type (Remdesivir, Chloroquine and Hydroxychloroquine, Ritonavir/Lopinavir, Ritonavir/Lopinavir + Interferon Beta, Others), Age Group (<10 Years, 10-19 Years, 20-29 Years, 30-80 Years, >80 Years) and Geography

LONDON, April 6, 2020 /PRNewswire/ -- As you know, Visiongain is a business information provider. One of our key aims is to help business grow – your business. It is also part of our remit to serve the companies that use us. We may not be able to develop a vaccine, but we can try and help the companies that do. And we will do that, by doing what we do – informing your industry.

So please register NOW to receive your FREE, business information guide to the current and future market of vaccines being designed for COVID-19. If this report can help you and your organisation structure a potential drug, business case, or regional targeting of resources etc – then please let us know.

This is all we can do, to help you do what your company does.

Our 150+ page report provides 100+ tables, charts, and graphs. Read on to discover the most key areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Novel Coronavirus (COVID-19) Drugs in Development Market. See how to exploit the opportunities.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/novel-coronavirus-covid-19-drugs-in-development-market-forecast-2020-2030/#download_sampe_div

Forecasts to 2030 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the global market and submarkets
Along with revenue prediction for the overall world market, there are 2 segmentations of the Novel Coronavirus (COVID-19) Drugs in Development market, with forecasts for 5 Drugs, 5 Age Groups, each forecasted at a global and regional level.

Global Novel Coronavirus (COVID-19) Drugs in Development Market by Drugs
• Remdesivir
• Chloroquine and hydroxychloroquine
• Ritonavir/lopinavir
• Ritonavir/lopinavir + interferon beta
• Others

Global Novel Coronavirus (COVID-19) Drugs in Development Market by Age Group
• <10 Years • 10-19 Years • 20-29 Years • 30-80 Years • >80 Years

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe

Asia-Pacific
• Japan
• China
• India
• Taiwan
• South Korea
• Rest of Asia-Pacific

Rest of the World

The report also includes profiles and for some of the leading companies in the Novel Coronavirus (COVID-19) Drugs in Development Market, with a focus on this segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., UK, Germany, Italy, India and China in particular, will continue to achieve high revenue growth to 2030.

Leading companies and the potential for market growth
Overall world revenue for Novel Coronavirus (COVID-19) Drugs in Development will surpass $xx billion in 2020, our work calculates. We predict strong revenue growth through to 2030.

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Novel Coronavirus (COVID-19) Drugs in Development Market report helps you
In summary, our 150+ page report provides you with the following knowledge:
• Revenue forecasts to 2030 for 2 segmentations of the Novel Coronavirus (COVID-19) Drugs in Development market, with forecasts for 5 Drugs, 5 Age Groups, each forecasted at a global and regional level– Discover the industry's prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2030 for 4 regional and 12 key national markets– See forecasts for the Novel Coronavirus (COVID-19) Drugs in Development market in North America, Europe, Asia-Pacific and Rest of the World.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Novel Coronavirus (COVID-19) Drugs in Development Market
• Find quantitative and qualitative analyses with independent predictions– Receive information that only our report contains, staying informed with this invaluable business intelligence.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to https://www.visiongain.com/report/novel-coronavirus-covid-19-drugs-in-development-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

Companies covered in the report include:

CanSino Biologics Inc
Entos Pharmaceuticals, Inc
Gilead
Inovio
King Abdullah International Medical Research Center
National Institute of Allergy and Infectious Diseases
Naval Medical Research Center
Novavax
Philipps University Marburg Medical Center
SAB Biotherapeutics Inc

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Top 26 Asthma & COPD Companies 2020-2030

Global Clinical Trial Management System Market Forecast 2020-2030

Clinical Trial Supply and Logistics Market for Pharma 2019-2029

Global ePharmacy Market 2018-2028

Global Influenza Vaccines Market Outlook 2019-2029

Global Live Vaccines Market Forecast 2020-2030

Global Vaccine Contract Manufacturing Market Report 2019-2029

Top 25 Vaccines Market Forecast to 2029

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.